FDA Accepts Letter of Intent to Qualify LSM by VCTE as First Non-Invasive Surrogate Endpoint in MASH Clinical Trials

Echosens Massachusetts

View original content:https://www.prnewswire.co.uk/news-releases/fda-accepts-letter-of-intent-to-qualify-lsm-by-vcte-fibroscan-as-first-non-invasive-surrogate-endpoint-in-mash-clinical-trials-302548054.html